Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | HTR7 | P34969 | 4/20 | 0.62 |
| ▸ | BCHE | P06276 | 2/20 | 0.60 |
| ▸ | ACHE | P22303 | 2/20 | 0.60 |
| ▸ | CCR3 | P51677 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512612 | 0.89 | ALDH1A1 (0.71) | ALDH1A1HTR7BCHEACHEKMT2A | |
| Hydrochloric Acid SCHEMBL3844581 | 0.88 | ALDH1A1 (0.69) | ALDH1A1HTR7BCHEACHEKMT2A | |
| SCHEMBL5373264 | 0.86 | ALDH1A1 (0.67) | ALDH1A1HTR7BCHEACHEKMT2A | |
| SCHEMBL11834324 | 0.86 | TSHR (0.67) | HTR7KMT2ADRD2 | |
| SCHEMBL11077909 | 0.85 | DRD2 (0.58) | ALDH1A1HTR7KMT2ADRD2 | |
| SCHEMBL5182996 | 0.84 | ALDH1A1 (0.76) | ALDH1A1HTR7KMT2ADRD2 | |
| SCHEMBL2834503 | 0.83 | ALDH1A1 (0.79) | ALDH1A1HTR7KMT2ADRD2 | |
| SCHEMBL11756285 | 0.82 | HTR1A (0.70) | HTR7DRD2 | |
| SCHEMBL6657455 | 0.82 | CCR3 (0.85) | CCR3 | |
| SCHEMBL7385393 | 0.82 | DRD2 (0.58) | ALDH1A1HTR7KMT2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099761-B1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-27 | — | — | EP | disclosed |
| US-20100063026-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | VILLAPHARMA RESEARCH S.L. (ES) | 2010-03-11 | — | — | US | disclosed |
| US-20100063026-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | VILLAPHARMA RESEARCH S.L. (ES) | 2010-03-11 | — | — | US | disclosed |
| WO-2008068272-A2 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063026-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | NQO2, NDUFB5, NDUFB7 | ALDH1A1 2506/4885HTR7 1601/4885BCHE 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.